Xinrui Medical Lands A Few Million Dollars In Series B Financing

Shanghai Xinrui Medical just received a few million dollars in Series B financing. This round of financing was led by Lucky Source Funds, the funds will be used for the clinical test of its Heartech system.

Xinrui Medical was founded in 2014, the company is the only company in China that committed to providing medical device treatment for heart failure, it also provides solutions for many service platform.

The founder of Xinrui Medical Qifeng Mei has 17 years of experience in medical device R&D, production management, design and development. The company's core product, the Heartech occluder system, has completed FIM clinical trials. Heart failure is a common syndrome of cardiovascular disease. China is estimated to have more than 10 million heart failure patients, and there are about 500,000 new heart failure patients every year.

At present, the treatment of heart failure is very limited and the curative effect is not good. The conventional treatment cannot meet the clinical needs, and new treatments are urgently needed. Xinrui Medical believes that they can improve this situation.

Lucky Source Funds is an equity investment firm focuses on biomedical health in China.